Abstract Number: 2548 • 2014 ACR/ARHP Annual Meeting
Primary Sjögren’s Syndrome Is Associated with Significant Cognitive Dysfunction
Background/Purpose Primary Sjögren’s syndrome (PSS) is an autoimmune exocrinopathy with multiple clinical manifestations. We aimed to evaluate the frequency and type of cognitive dysfunction and…Abstract Number: 2547 • 2014 ACR/ARHP Annual Meeting
The Impact of Primary Sjögren’s Syndrome on Female Sexual Function
Background/Purpose . Primary Sjögren's syndrome (pSS) is a chronic and disabling disease, characterized by sicca symptoms of the eyes and mouth as well as fatigue.…Abstract Number: 2546 • 2014 ACR/ARHP Annual Meeting
Metabolic Disorders Causing Fatigue in Sjogren’s Syndrome
Background/Purpose Sjogren’s syndrome (SS) is a complex disorder involving both the innate and immune system. Fatigue is a common feature of the disease. Mitochondrial dysfunction…Abstract Number: 2545 • 2014 ACR/ARHP Annual Meeting
Risk of Cervical Root and Incisal Caries in Patients with Sjogren’s Syndrome
Risk of Cervical Root and Incisal Caries in Patients with Sjogren's SyndromeBackground/Purpose Pathologic (cervical root and incisal caries) cause significant morbidity in patients with Sjogren's…Abstract Number: 2544 • 2014 ACR/ARHP Annual Meeting
How Does a Younger Age at the Onset of Sjögren’s Syndrome (pSS) Influence the Clinical Presentation and the Clinical Course of the Disease?
Background/Purpose: (1) To analyze the clinical presentation and the clinical course of Sjögren’s Syndrome (pSS) in Caucasian patients with an “early-onset” pSS and (2) to compare…Abstract Number: 2543 • 2014 ACR/ARHP Annual Meeting
Anti-Ro/SSA Positive Incomplete Sjögren’s Syndrome
Background/Purpose: Sjögren’s syndrome (SS) is a systemic disease characterized by dry eyes and mouth resulting from immune mediated damage and dysfunction of the lacrimal and…Abstract Number: 2542 • 2014 ACR/ARHP Annual Meeting
La Positive, Ro60 Negative Subset of Primary Sjögren’s Syndrome Is a Reality
Background/Purpose Twenty-nine sera from 348 primary Sjögren’s syndrome patients were identified as anti-Ro60 (anti-SSA) negative and anti-La (anti-SSB) positive by immunodiffusion, line immunoassays and multiplex…Abstract Number: 2541 • 2014 ACR/ARHP Annual Meeting
Autoantibodies in Pediatric Sjogren’s Patients
Background/Purpose Sjogren’s syndrome (SS) is a common autoimmune disease involving the salivary and lacrimal glands along with various other organs. It is generally seen in…Abstract Number: 2540 • 2014 ACR/ARHP Annual Meeting
Sjö™, an Advanced Diagnostic Panel for Detection of Sjögren’s Syndrome Autoantibodies
Background/Purpose Sjögren’s syndrome (SS) is a complex autoimmune disease involving the salivary and lacrimal glands along with various systemic manifestations. It is a difficult disease to…Abstract Number: 2523 • 2014 ACR/ARHP Annual Meeting
Are Biologic Agents Effective on the Treatment of Secondary Amyloidosis: A Multicenter Report on Turkish Rheumatoid Arthritis and Ankylosing Spondylitis Patients
Background/Purpose Biologic drugs including anti-TNF agents have been used in the treatment of secondary amyloidosis, however, there is no controlled study concerning the efficacy of…Abstract Number: 2522 • 2014 ACR/ARHP Annual Meeting
Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations
Background/Purpose To evaluate the effects of infliximab (Ifx) dose increase in active rheumatoid arthritis (RA) patients, presenting different serum infliximab concentrations.Methods Retrospective study including 42…Abstract Number: 2521 • 2014 ACR/ARHP Annual Meeting
Analysis on Predictors for Long-Term Clinical Efficacies of Golimumab in Patients with Rheumatoid Arthritis
Background/Purpose The GO-FORTH, phase 2/3 clinical trial was conducted to examine the efficacy and safety of Golimumab (GLM) plus MTX in Japanese patients (pts) with…Abstract Number: 2520 • 2014 ACR/ARHP Annual Meeting
Patient, Genetic and Disease Factors Influence the Response to the Disease Modifying Anti-Rheumatic Drug Leflunomide
Background/Purpose . Leflunomide is a disease modifying anti-rheumatic drug that is used in the treatment of rheumatoid arthritis (RA). Leflunomide is converted to teriflunomide by the…Abstract Number: 2518 • 2014 ACR/ARHP Annual Meeting
What Is the Level of Agreement Between Disease Activity Indices and Response Criteria Among Rheumatoid Arthritis Patients Treated with TNF Inhibitors?
Background/Purpose: Several standardized response criteria and disease activity indices are used to assess treatment efficacy in rheumatoid arthritis (RA). These measures comprise different types and…Abstract Number: 2519 • 2014 ACR/ARHP Annual Meeting
Are Patients with Rheumatoid Arthritis Initiating a TNF Biologic Comparable to Patients Initiating a Non TNF?
Background/Purpose: Comparative research has gained attention in the field of Rheumatology. Evaluations of baseline characteristics in patients receiving similar treatments are critical in the…
ACR Meeting Abstracts